Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Puretech Health Plc ADR
(NQ:
PRTC
)
22.45
UNCHANGED
Streaming Delayed Price
Updated: 3:34 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Puretech Health Plc ADR
< Previous
1
2
3
4
5
Next >
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
November 29, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
November 17, 2023
From
PureTech Health plc
Via
Business Wire
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
November 14, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Present at Two Upcoming Investor Conferences
October 17, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
October 11, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
October 04, 2023
From
PureTech Health plc
Via
Business Wire
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
September 28, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
September 27, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Health plc – Half-Year Report
August 29, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Half-Yearly Results
August 22, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
August 01, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
June 21, 2023
From
PureTech Health plc
Via
Business Wire
Results of PureTech's Annual General Meeting
June 13, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the Jefferies Healthcare Conference
May 24, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
May 09, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
May 04, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Announces Annual Results for Year Ended December 31, 2022
April 28, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
April 25, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
April 17, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Results
April 13, 2023
From
PureTech Health plc
Via
Business Wire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 23, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
March 23, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the Barclays Global Healthcare Conference
March 01, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
February 27, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
February 14, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the SVB Securities Global Biopharma Conference
February 01, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Provides End of Year Report on Key Progress
December 22, 2022
From
PureTech Health plc
Via
Business Wire
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
December 19, 2022
From
PureTech Health plc
Via
Business Wire
PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
December 13, 2022
From
PureTech
Via
Business Wire
PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
From
PureTech Health plc
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.